AKT1 and prostate carcinoma: Despite promising results in early preclinical studies, targeting the PI3K-AKT-mTOR pathway in prostate cancer appeared to be challenge due to numerous feedback and feedforward loops and redundancy mechanisms that prevent complete blockage of the pathway [6].